In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized...
This roundup of COVID-19 news includes results of a phase 2 trial of an antiviral triple therapy, the first antigen test authorized by the FDA, pneumonia guidelines, COVID-19–related illness in children,...
It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
